Hemispherx Biopharma Awarded $770,852 by Federal Judge
January 15, 2015 08:30 ET
|
AIM ImmunoTech Inc.
WILMINGTON, Del., Jan. 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that after prevailing in a federal lawsuit brought against the...
Hemispherx Biopharma Reports on Annual Stockholder Meeting
November 14, 2014 16:00 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Nov. 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE MKT:HEB) announced that it held its 2014 Annual Meeting of Stockholders on November 12, 2014. Final voting results will...
Hemispherx Biopharma Reports New Evidence -- Based Potential of Ampligen(R) Against Ebola Virus Disease (EVD)
October 30, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today a new peer reviewed publication entitled, "The Quest for...
Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola
October 20, 2014 12:00 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), has retained Squire Patton Boggs (SPB) to serve as its global government...